NCT04387903

Brief Summary

The aim of this study is to outline the incidence of early and late reoperation after PD, examine the risk factors for early surgical intervention and its impact on the surgical outcome, hospital stay, diseases recurrence and patient survival, address variable indications for late readmission and reoperation after PD and its impact on patient survival and disease recurrence.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2000

Longer than P75 for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2000

Completed
18.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2018

Completed
2 years until next milestone

First Submitted

Initial submission to the registry

May 10, 2020

Completed
4 days until next milestone

First Posted

Study publicly available on registry

May 14, 2020

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2020

Completed
Last Updated

May 14, 2020

Status Verified

May 1, 2020

Enrollment Period

18.3 years

First QC Date

May 10, 2020

Last Update Submit

May 10, 2020

Conditions

Keywords

Pancreaticoduodenectomy, pancreatic fistula, pancreatic cancer, reoperation

Outcome Measures

Primary Outcomes (2)

  • Patient survival

    The duration between surgical intervention to patient death

    2-20 years after surgery

  • Tumor recurrence

    Duration between surgery and recurrence of periampullary tumors based on radiological or endoscopic investigations.

    2-20 years

Secondary Outcomes (3)

  • Hospital stay after reoperation

    10-90 days after reoperation

  • Morbidity after reoperation

    10-90 days after reoperation

  • Risk factors for surgical reoperation

    Before surgical intervention

Study Arms (2)

Reoperation group

The group of patients who underwent pancreaticduodenectomy for management of periampullary tumors and required surgical reintervention afterwards for management of procedure-related complications as pancreatic fistula, bleeding, abdominal collection, biliary fistula, gastric fistula.

Procedure: Surgical re-interventionafter pancreaticoduodenectomy

No reoperation group

The group of patients who underwent pancreaticoduodenectomy for management of periampullary tumors and did not require surgical reintervention.

Procedure: Surgical re-interventionafter pancreaticoduodenectomy

Interventions

Mandatory surgical management of complications after pancreatico-duodenectomy through peritoneal lavage, draiange, repair of fistula, completion pancreatectomy, control of bleeding, bowel resection, and feeding jejunostomy.

No reoperation groupReoperation group

Eligibility Criteria

Age15 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

This is a retrospective cohort study of all patients who underwent PD for periampullary malignant lesions in the duration between January 2000 and May 2018. Preoperative assessment was performed by clinical examination and detailed laboratory investigations. Assessment of local extension of the tumor and metastatic work-up was performed by pelvi-abdominal ultrasound (US), triphasic abdominal computerized tomography (CT) with angiographic assessment of the surrounding vessels, bone survey, and chest X-ray. Preoperative endoscopic retrograde cholangiopancreatography (ERCP) for preoperative biliary drainage was performed in selected cases

You may qualify if:

  • all patients who underwent pancreaticoduodenectomy for periampullary malignant lesions in the duration between January 2000 and May 2018

You may not qualify if:

  • Pancreaticoduodenectomy performed for benign tumors, recurrent malignant tumors, chronic pancreatitis, or inflammatory strictures were excluded from the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Pancreatic NeoplasmsPancreatic Fistula

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteNeoplasmsEndocrine Gland NeoplasmsDigestive System DiseasesPancreatic DiseasesEndocrine System DiseasesDigestive System FistulaFistulaPathological Conditions, AnatomicalPathological Conditions, Signs and Symptoms

Study Officials

  • Ayman El Nakeeb, md

    Professor of Surgery, Gastrointestinal Surgical Center

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Lecturer of general surgery

Study Record Dates

First Submitted

May 10, 2020

First Posted

May 14, 2020

Study Start

January 1, 2000

Primary Completion

May 1, 2018

Study Completion

August 1, 2020

Last Updated

May 14, 2020

Record last verified: 2020-05

Data Sharing

IPD Sharing
Will not share

The data will be prepared as a research paper and the cohort results will be published in a scientific journal.